Back to top

crispr: Archive

Zacks Equity Research

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

REGNPositive Net Change VRTXPositive Net Change ABUSNo Net Change NTLAPositive Net Change